Business Wire

MINDEROO-FOUNDATION

9.5.2022 08:23:07 CEST | Business Wire | Press release

Share
Global Plastic Watch: Satellite Eyes Pinpoint Waste From Space to Reduce Ocean Pollution

A cutting-edge new tool developed by Minderoo Foundation has identified thousands of waste sites across 25 countries for the first time using advanced satellite data technology and machine learning to measure piles of plastic waste from space.

Global Plastic Watch (globalplasticwatch.org ) is a tool which combines earth observation with artificial intelligence to create the first-ever near-real-time high-resolution map of plastic pollution. This is the largest open-source dataset of plastic waste across dozens of countries. The aim of the tool is to help authorities to better manage plastic leakage into the marine environment.

Global Plastic Watch uses remote sensing satellite imagery from the European Space Agency and a first-of-its-kind machine learned model created in collaboration with award winning Digital Product Agency for the Environment, Earthrise Media . The tool is able to determine the size and scale of land-based plastic waste sites, a major factor in fueling the growing problem of plastic pollution of the world’s rivers and oceans.

The data gathered provides a historical first and authoritative insight into one of the world’s most intractable environmental challenges – a deluge of plastic pollution which is threatening the oceans, harming communities, marine life, animal and human health. By using it, governments, industry and communities can evaluate and monitor the risk of land-based plastic waste sites, as well as prioritise investments in solutions.

The countries mapped so far include all of South-East Asia, Australia, and the countries identified by research published in Science Advances as accounting for high rates of plastic emissions into the ocean.

Dr Andrew Forrest AO, Chairman and Co-Founder of the Minderoo Foundation described data and transparency as important tools to fight plastic waste, and until now, it has been difficult to effectively identify and measure plastic waste build-up in a systematic, standardised way.

“Generally, the world has no idea how dangerous plastic waste is to the organic environment, particularly humans. The destination for every piece of plastic is nano-plastic, which has both poisonous and cutting attributes able to mutilate cells and even penetrate the human blood brain barrier,” Dr Forrest said.

“Preventing illegal and legal plastic waste stockpiles entering the oceanic environment is critical to limit this harm. Once in the ocean, through both mixing, absorption and ingestion by animals, this plastic will officially enter the human environment.

Using artificial Intelligence and satellite data, Minderoo Foundation has produced the first-ever map of plastic waste build up. Most of our data about plastic waste comes from models and estimates. Now our understanding is informed by real data that can be used to guide solutions.

Global Plastic Watch arms governments and researchers around the world with data that can better guide effective waste management interventions, ensuring land-based waste doesn’t end up in our oceans,” Dr Forrest said. “We want to work with governments to ensure this tool can also help to support policy change where needed.”

Dr Fabien Laurier, Lead for Technology and Innovation, and Ocean Conservation at Minderoo Foundation said some of the Global Plastic Watch findings were surprising.

“We know that land-based leakage contributes up to 91 per cent of the plastic waste that enters the ocean,” Dr Laurier said. “Global Plastic Watch has revealed that many large-scale waste sites across the first 25 countries we have mapped were previously undocumented and the number of sites is much higher than expected.”

The government of Indonesia is working with Minderoo Foundation to increase its recycling capacity to double recycling rates by developing capacity for an additional one million tonnes per year by 2025.

Dr Nani Hendiarti, Deputy for Environment and Forestry Management Coordination, Coordinating Ministry for Maritime Affairs and Investment, Indonesia, congratulated Minderoo Foundation on the public launch of the Global Plastic Watch.

“Global Plastic Watch is very helpful for identifying undocumented or illegal waste dump sites in Indonesia,” Dr Hendiarti said. “That has enabled us to prioritise areas in need of better waste management policies and actions. Therefore, it plays an integral role in accelerating the government’s waste management achievements across all regions in the country.”

Indonesian National Plastic Action Partnership (NPAP) Chair, Sri Indrastuti Hadiputranto, said tackling the challenge of plastic pollution in Indonesia, like in many other places in the world is going to require a collaborative effort from the public, private and civil society sectors, and its measurement is without exception.

“Global Plastic Watch is a data aggregator and monitoring platform on plastic waste,” Ms. Hadiputranto said. “It’s a timely innovation for policymakers, practitioners and advocates that believe in the importance of evidence-based policy making to advance our goal in reducing 70 per cent of ocean leakage by 2025. I believe more data-oriented innovations like Global Plastic Watch will lead us to a more sustainable policy outcome and improving collaborations in data collections in Indonesia.”

Global Plastic Watch is a tool aimed at supporting country-level efforts to understand the magnitudes and effects of land-based plastic waste sites, to enable them to better address undocumented sites and monitor those that pose environmental and health concerns. The data is also expected to guide direct investments in waste infrastructure in the areas that need it the most.

The development of the Global Plastic Watch tool follows the Plastic Waste Makers Index released in 2021, that revealed the true scale and sources of the global plastic waste crisis.

Globally, a 30 per cent increase in the production of single-use plastic is projected over the next five years. The Minderoo Foundation No Plastic Waste initiative believes this growth in production will lead to an extra three trillion items of throwaway plastic waste by 2025.

Global Plastic Watch will continue to work with partners to refine the Artificial Intelligence model and technology to further increase its accuracy as it expands its coverage to new sites and countries throughout 2022.

Global Plastic Watch site: globalplasticwatch.org
Global Plastic Watch project site: Minderoo.org/global-plastic-watch/

LINK TO PHOTOS (Password: k3YBL4TciY) | INTERVIEWS AND B-ROLL HERE | 2:17 VIDEO EDIT WITH ENGLISH NARRATION HERE |

About Minderoo Foundation:

Established by Andrew and Nicola Forrest in 2001, Minderoo Foundation is a modern philanthropic organisation seeking to break down barriers, innovate and drive positive, lasting change. Minderoo Foundation is proudly Australian, with key initiatives spanning from ocean research and ending slavery, to collaboration against cancer and building community projects.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye